/a//content.14388
...Mixing, granulating, milling, molding, of components, drug product containers, formulating.....whether they use terminal sterilization, three initial batches in the stability.. Sampling.....Therefore, under the Federal Food, all established standards, specifications, Drug, and..
http://www.fda.gov/cder/dmpq/fr5396.pdf (score=100)

HUMAN DRUG CGMP NOTES September 1998
...Similarly, if stability testing that is supposed to be performed prior to the end of the.....Welcome to another issue of Human Drug CGMP Notes, our periodic memo on CGMP for human use.....components, drug product containers, closures, labeling, in-process materials and drug..
http://www.fda.gov/cder/hdn/cnotes98.htm (score=42)

HUMAN DRUG CGMP NOTES June 1966
...used in the delivery of a medical drug product is considered an integral part of the drug.....Where stability testing reveals that the BPC is stable for the intended period of use, or.....84(d), Testing and approval or rejection of components, drug product containers, and..
http://www.fda.gov/cder/hdn/hdn696.htm (score=33)

HUMAN DRUG CGMP NOTES December, 1996
...Is it acceptable for a firm to use drug components, drug product containers, or drug product.....However, because the technology may not have been available, older applications lacking.....Is it acceptable for a firm to use drug components, drug product containers, or drug product..
http://www.fda.gov/cder/hdn/cnotesd6.htm (score=33)

HUMAN DRUG CGMP NOTES March 1997
...Welcome to another edition of Human Drug CGMP Notes, our periodic memo on CGMP for human.....166, Stability testing; February, 1987 "Guideline For Submitting Documentation For The.....84(c)(6), Testing and approval or rejection of components, drug product containers, and..
http://www.fda.gov/cder/hdn/cnotes37.htm (score=33)

Guidance For the Submission of Documentation for Sterilization Process
...Documentation for the Stability of Human Drugs and Biologics"and to the Center for.....other processes should be addressed as each applies to the drug product,sterile packaging.....The sterilization and depyrogenation processes used for containers,closures, equipment..
http://www.fda.gov/cber/gdlns/sterval.pdf (score=15)

For the Submission of Documentation for Sterilization Process
...Documentation for the Stability of Human Drugs and Biologics"and to the Center for.....other processes should be addressed as each applies to the drug product,sterile packaging.....The sterilization and depyrogenation processes used for containers,closures, equipment..
http://www.fda.gov/cder/guidance/cmc2.pdf (score=15)

PET Drug Products … Current Good Manufacturing Practice (CGMP)
...or lot, of a PET drug typically consists of one multiple-dose vial containing the PET drug.....stability parameters include radiochemical identity and purity, appearance, pH, stabilizer.....evaluation can include testing of the material (see Section VI, Control of Components, 276..
http://www.fda.gov/cder/guidance/4259dft.pdf (score=14)

HUMAN DRUG CGMP NOTES March 1998
...For example, microbial content that adversely affects product stability, would be.....Is the employment of HIV infected workers in drug manufacturing facilities in conformance.....components, drug product containers, closures, in-process materials, and drug products..
http://www.fda.gov/cder/hdn/cnotes38.htm (score=14)

PET Drug Products - Current Good Manufacturing Practice (CGMP)
...Appropriate parameters should be evaluated to establish and document the stability of a PET drug product.....Large PET centers that handle large numbers of components and PET drug products should.....Stability testing of the PET drug product should be performed at the highest radioactive..
http://www.fda.gov/cder/guidance/4259dft.htm (score=13)

Microsoft Word - CNOTES vol 1 no 4 dec 93.doc
...Abbreviated New Drug Applications; testing at each stability point? Preapproval Inspection.....approval or rejection of components, drug .. way to avoid problems with data manipulation.....this does not mean that stability testing protocols .. of 1994, will apply to all labeling..
http://www.fda.gov/cder/dmpq/CNOTES%20vol%201%20no%204%20dec%2093.pdf (score=13)

FDA Concept Paper: Drug Products That Present Demonstrable Difficulties for...
...Factors such as drug stability in the vehicle, the specific product use, and the site of.....Since TDS products may contain volatile components, it is critical that the stability of the volatile components be.....For plastic components, there is the potential for drug adsorption into the plastic, swelling of the plastic, and leaching of..
http://www.fda.gov/cder/fdama/difconc.htm (score=6)

MDI and DPI Drug Products
...establish a set of criteria to which a drug substance or drug product should conform using.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....recommended for inclusion in the application regarding the components, manufacturing..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=5)

HUMAN DRUG CGMP NOTES December 1998
...84, Testing and approval or rejection of components, drug product containers, and closures.....84, Testing and approval or rejection of components, drug product containers, and closures.....Welcome to another edition of Human Drug CGMP Notes, our periodic memo on CGMP for human..
http://www.fda.gov/cder/hdn/cnotesd8.htm (score=42)

...84 pertains to the testing and approval or rejection of components, drug product containers, and.....Because a dosage form is typically a complex unit, such changes may have an impact on drug product.....82 governs the receipt and storage of untested components, drug product containers, and..
http://www.fda.gov/cber/genadmin/cgmp.txt (score=22)

GUIDE TO INSPECTIONS OF DOSAGE FORM DRUG MANUFACTURER'S - CGMPR'S
...Determine the validity, and accuracy of the firm's inventory system for drug components.....o Studies of the stability and resistance of the selected organism to the specific.....Components must be handled in accordance with the drug CGMP's including components used in the research and..
http://www.fda.gov/ora/inspect_ref/igs/dose.html (score=14)

...Under the QS regulation, for a combination product with a drug constituent part, yield and stability requirements would be.....125, may not need to comply with regulations related to receipt and storage of untested.....For example, for a drug-coated device, the drug constituent part would be subject only to..
http://www.fda.gov/cder/guidance/OCLove1dft.doc (score=13)

Current Good Manufacturing Practice for Combination Products
...Under the QS regulation, for a combination product with a drug constituent part, yield and stability requirements would be.....125, may not need to comply with regulations related to receipt and storage of untested.....For example, for a drug-coated device, the drug constituent part would be subject only to..
http://www.fda.gov/cder/guidance/OCLove1dft.htm (score=13)

Microsoft Word - CNOTES vol 2 no 3 sep 94.doc
...the drug product, the quantities are in the parts-per-million range. This does not mean.....basis of stability testing on the biobatch and any.. when the application is approved, the.....approval or rejection of components, drug.. code (for scanners) or area (for machine..
http://www.fda.gov/cder/dmpq/CNOTES%20vol%202%20no%203%20sep%2094.pdf (score=13)

Las Vegas Injury Lawyer